Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 152

1.

The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis.

Blomberg B, Spinaci S, Fourie B, Laing R.

Bull World Health Organ. 2001;79(1):61-8. Epub 2003 Nov 5.

PMID:
11217670
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Fixed-dose combination drugs for tuberculosis: application in standardised treatment regimens.

Blomberg B, Fourie B.

Drugs. 2003;63(6):535-53. Review.

PMID:
12656652
[PubMed - indexed for MEDLINE]
3.

Structures required, roles and responsibilities in maintaining laboratories for quality assurance of anti-tuberculosis fixed-dose combinations in accordance with the IUATLD/WHO statement.

Fourie PB, Spinaci S.

Int J Tuberc Lung Dis. 1999 Nov;3(11 Suppl 3):S368-70; discussion S381-7.

PMID:
10593720
[PubMed - indexed for MEDLINE]
4.

Implementation of fixed-dose combinations in tuberculosis control: outline of responsibilities.

Chaulet P.

Int J Tuberc Lung Dis. 1999 Nov;3(11 Suppl 3):S353-7; discussion S381-7.

PMID:
10593717
[PubMed - indexed for MEDLINE]
5.

Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.

Agrawal S, Singh I, Kaur KJ, Bhade SR, Kaul CL, Panchagnula R.

Int J Pharm. 2004 May 19;276(1-2):41-9.

PMID:
15113612
[PubMed - indexed for MEDLINE]
6.

Rifampicin bioavailability: a review of its pharmacology and the chemotherapeutic necessity for ensuring optimal absorption.

Ellard GA, Fourie PB.

Int J Tuberc Lung Dis. 1999 Nov;3(11 Suppl 3):S301-8; discussion S317-21. Review.

PMID:
10593709
[PubMed - indexed for MEDLINE]
7.

Availability of quality fixed-dose combinations for the treatment of tuberculosis: what can we learn from studying the World Health Organization's vaccine model?

Blomberg B, Kitler ME, Milstien J, Dellepiane N, Fanning A, Norval PY, Spinaci S.

Int J Tuberc Lung Dis. 1999 Nov;3(11 Suppl 3):S371-80; discussion S381-7.

PMID:
10593721
[PubMed - indexed for MEDLINE]
8.

Estimate of the global market for rifampicin-containing fixed-dose combination tablets.

Norval PY, Blomberg B, Kitler ME, Dye C, Spinaci S.

Int J Tuberc Lung Dis. 1999 Nov;3(11 Suppl 3):S292-300; discussion S317-21.

PMID:
10593708
[PubMed - indexed for MEDLINE]
9.

Fixed dose combinations for tuberculosis: Lessons learned from clinical, formulation and regulatory perspective.

Panchagnula R, Agrawal S, Ashokraj Y, Varma M, Sateesh K, Bhardwaj V, Bedi S, Gulati I, Parmar J, Kaul CL, Blomberg B, Fourie B, Roscigno G, Wire R, Laing R, Evans P, Moore T.

Methods Find Exp Clin Pharmacol. 2004 Nov;26(9):703-21. Review.

PMID:
15632956
[PubMed - indexed for MEDLINE]
10.

Bioequivalence assessment of rifampicin, isoniazid and pyrazinamide in a fixed dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol vs. separate formulations.

Agrawal S, Singh I, Kaur KJ, Bhade SR, Kaul CL, Panchagnula R.

Int J Clin Pharmacol Ther. 2002 Oct;40(10):474-81.

PMID:
12395981
[PubMed - indexed for MEDLINE]
11.

Requirements for anti-tuberculosis drug tender requests.

Trébucq A, Caudron JM, Pinel J.

Int J Tuberc Lung Dis. 1999 Nov;3(11 Suppl 3):S358-61; discussion S381-7.

PMID:
10593718
[PubMed - indexed for MEDLINE]
12.

Proposed minimum registration requirements for fixed-dose combination anti-tuberculosis drugs.

Fourie PB.

Int J Tuberc Lung Dis. 1999 Nov;3(11 Suppl 3):S362-7; discussion S381-7.

PMID:
10593719
[PubMed - indexed for MEDLINE]
13.

Assessment of bioequivalence of rifampicin, isoniazid and pyrazinamide in a four drug fixed dose combination with separate formulations at the same dose levels.

Agrawal S, Kaur KJ, Singh I, Bhade SR, Kaul CL, Panchagnula R.

Int J Pharm. 2002 Feb 21;233(1-2):169-77.

PMID:
11897421
[PubMed - indexed for MEDLINE]
14.

[Tuberculosis in Asia].

[No authors listed]

Kekkaku. 2002 Oct;77(10):693-7. Japanese.

PMID:
12440145
[PubMed - indexed for MEDLINE]
15.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
[PubMed - indexed for MEDLINE]
16.

Evaluation of bioequivalence of isoniazid and pyrazinamide in three and four drugs fixed dose combinations using WHO simplified protocol.

Panchagnula R, Sancheti P, Rungta S, Agrawal S, Kaul CL.

Pharmacol Res. 2003 Oct;48(4):383-7.

PMID:
12902209
[PubMed - indexed for MEDLINE]
17.

Tuberculosis drug issues: prices, fixed-dose combination products and second-line drugs.

Laing RO, McGoldrick KM.

Int J Tuberc Lung Dis. 2000 Dec;4(12 Suppl 2):S194-207. Review.

PMID:
11144553
[PubMed - indexed for MEDLINE]
18.

Fixed-dose combination chemotherapy (Rifater/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up.

Su WJ, Perng RP.

Int J Tuberc Lung Dis. 2002 Nov;6(11):1029-32.

PMID:
12475151
[PubMed - indexed for MEDLINE]
19.

Detection of substandard fixed-dose combination tuberculosis drugs using thin-layer chromatography.

Kenyon TA, Kenyon AS, Kgarebe BV, Mothibedi D, Binkin NJ, Layloff TP.

Int J Tuberc Lung Dis. 1999 Nov;3(11 Suppl 3):S347-50; discussion S351-2.

PMID:
10593716
[PubMed - indexed for MEDLINE]
20.

[Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].

Saito W, Nagayama N, Miyamoto M, Hara H, Suzuki J, Masuda K, Baba M, Tamura A, Nagai H, Akagawa S, Kawabe Y, Machida K, Kurashima A, Yotsumoto H.

Kekkaku. 2003 Oct;78(10):611-7. Japanese.

PMID:
14621568
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk